In the News | Friends of Cancer Research

You are here

In the News

New York Times- Merging the Senate Bills

By David M. Merszenhorn, Senate Democrats and White House officials met on Monday evening to discuss how to merge the two versions of the Senate’s health care legislation,

 and Democratic aides said they were aiming to have a combined bill “mostly baked” by the end of this week.

Philadelphia Inquirer- A few seconds for science

 In fact, a recent Research!America poll showed that most Americans cannot name a single living scientist.

Reuters- Rep. DeLauro, Administration Urge Congress to Improve the Safety of Imported Food

Today convened the 2nd Annual Global Food Safety Policy Forum with the Centerfor Science in the Public Interest (CSPI) in Washington, DC,

 bringing togetherpolicymakers and private experts from around the globe to discuss solutionsthat improve food supply in the United States and worldwide.    

Fortune-FDA chief: Regaining your trust

 In May, Margaret Hamburg became the 21st commissioner of the Food and Drug Administration, a beleaguered agency that has long been criticized for its mishandling of food crises and for drug recalls such as the Vioxx debacle.

Hamburg's grounding is in science and public health. A physician, she was the commissioner of New York City's Department of Public Health from 1990 to 1997 and later became vice president for Biological Programs and senior scientist at the Nuclear Threat Initiative foundation.

AP- Another GOP senator open to health overhaul

A second Republican senator signaled Wednesday she's open to voting for sweeping health care legislation this year, putting President Barack Obama closer to a historic achievement that has eluded generations of Democratic leaders.

RPM Report Interview with Ellen Sigal

FDA and Cancer Drug Development: An Advocate’s View

Friends of Cancer Research (www.focr.org) has been among the most vocal supporters of a robust FDA review process for oncology drugs. Chair & Founder Dr. Ellen Sigal has taken the advocacy group from a one-person shop to an organization with strong ties to the agency and the lawmakers on Capitol Hill who matter most to the future of cancer treatment.

RPM Report- FDA and Cancer Drug Development: An Advocate’s View

By Ramsey Baghdadi, Friends of Cancer Research (www.focr.org) has been among the most vocal supporters of a robust FDA review process for oncology drugs.

 Chair & Founder Dr. Ellen Sigal has taken the advocacy group from a one-person shop to an organization with strong ties to the agency and the lawmakers on Capitol Hill who matter most to the future of cancer treatment.

The RPM Report: How do you work with the other cancer advocacy groups?

New York Times- Health Care Bill Gets Green Light in Cost Analysis

By ROBERT PEAR and DAVID M. HERSZENHORN, The Senate Finance Committee legislation to revamp the health care system would provide coverage to 29 million uninsured Americans

but would still pare future federal deficits by slowing the growth of spending on medical care, the nonpartisan Congressional Budget Office said Wednesday.

Wall Street Journal- Hospitals Find Way to Make Care Cheaper -- Make It Better

 

By Thomas M. Burton,  Be it cereal or cars, buyers usually have an idea of how good the products are and how much they cost before they buy them.

That's not how U.S. health care works. Patients rarely know which hospitals offer top-quality lung or aortic surgery, and which are more likely to harm them. Hospitals don't compete on price and rarely publish measurements of their quality, if they measure it at all.

New York Times- For N.I.H. Chief, Issues of Identity and Culture

 

By GARDINER HARRIS, He drives a Harley-Davidson, wears a black leather jacket on his back and his religion on his sleeve, and plays a custom guitar with big-name rock stars.

All that would seem to have nothing to do with Dr. Francis S. Collins’s day job as the new director of the National Institutes of Health. Except that at the institutes, such things do matter.

Pages